Dinutuximab

From WikiMD

Information about Dinutuximab

Dinutuximab is a recombinant chimeric monoclonal antibody to GD2 which is used as an anticancer agent in combination with other antineoplastic agents in the treatment of neuroblastoma. 

Liver safety of Dinutuximab

Transient asymptomatic elevations in serum aminotransferase levels are common during dinutuximab therapy, but it has not been linked to instances of clinically apparent liver injury

Mechanism of action of Dinutuximab

Dinutuximab (din" ue tux' i mab) is a mouse-human chimeric monoclonal IgG1 antibody to disialoganglioside (GD2), a cell surface glycolipid that is present in low concentrations on skin, neural or peripheral nerve cells and is overexpressed on neuroblastoma cells.  Engagement of dinutuximab with GD2 triggers antibody dependent cell cytotoxicity.  Cytotoxicity of dinutuximab is increased by coadministration of granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin 2 (IL2) because of their effects on neutrophils, macrophages and immune effector cells, for which reason dinutuximab is usually combined with these cytokines. 

FDA approval information for Dinutuximab

Dinutuximab was approved for use in neuroblastoma in the United States in 2015.  Current indications are for its administration with IL2 or GM-CSF added to standard isotretinoin therapy of high risk pediatric patients with neuroblastoma. 

Dosage and administration for Dinutuximab

Dinutuximab is available in liquid solution in single use vials of 17.5 mg in 5 mL (3.5 mg/mL) under the brand name Unituxin.  Dinutuximab is given by slow intravenous infusion (over 10 hours) in a dose of 17.5 mg/m2 daily for 4 consecutive days, repeated in up to 5 cycles.  Premedication with hydration, diphenhydramine, acetaminophen and a potent analgesic [such as morphine] is recommended. 

Side effects of Dinutuximab

Adverse side effects of the combination immunotherapy are frequent and can be severe.  These side effects include infusion reactions, nausea and vomiting, rash, hypotension, capillary leak syndrome, neuropathic pain and peripheral neuropathy.  Less common, but potentially severe side effects include severe hypersensitivity reactions, neurologic and ophthalmologic toxicities, transverse myelitis, reversible posterior leukoencephalopathy syndrome, severe infections, bone marrow suppression, electrolyte abnormalities and embryo-fetal toxicity.

 


The article on Dinutuximab is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more


edit 

About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Dinutuximab or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.

Pubmed.png Uptodate.png Wikipedia Reddit YouTube videos
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Dinutuximab">Dinutuximab</a>

  • Individual results may vary for weight loss from our sponsors.